An open-label study to define the safety tolerability and clinical activity of deutetrabenazine (Austedo) in adult study subjects with dystonia

An open-label study to define the safety tolerability and clinical activity of deutetrabenazine (Austedo) in adult study subjects with dystonia
Recruiting
18 years - 99 years
All
Phase 3
15 participants needed
1 Location

Brief description of study

The purpose of this research study is to explore the safety and tolerability of the daily oral administration of deutetrabenazine, whose trade name is Austedo, in adults with dystonia.

Detailed description of study

The study is being conducted at the Parkinson’s Disease and Movement Disorders Center of the University of Pennsylvania. Approximately 15 men and women over the age of 18 who have been diagnosed with dystonia will take part in this study. Participants will be patients whose dystonia is being managed at the University of Pennsylvania or are referred to this center for the purpose of participating in this trial. Your participation in the study will last for up to 13 weeks, with the length of time depending on how long it takes to determine the appropriate dose of Austedo for you. 

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: dystonia,neuro
  • Age: 18 years - 99 years
  • Gender: All


Updated on 19 Feb 2024. Study ID: 834104

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.